企业QQ
官方微信
MTI-GlobalStem公司成立于2006年，最初名为GlobalStem，在2010年被MolecularTransfer公司(MTI)收购，总部位于美国马里兰州盖瑟斯堡，致力于开发和推广细胞转染、神经生物学以及干细胞研究所用的工具和试剂。此外，这家公司还提供干细胞、分化神经元和大规模的细胞培养制造服务。
MTI团队的科学家也并非等闲之辈，他们参与开发了转染、转化、核酸技术以及基因表达领域的多个知名产品。据介绍，这些科学家在BRL/LifeTechnologies任职期间曾领导著名的转染试剂Lipofectamine的开发。他们还与加州大学旧金山分校的DougHanahan教授合作，开发并推广了赫赫有名的DH5α？和DH10B？系列。
如今，MTI-GlobalStem凭借在转染、神经生物学和干细胞生物学方面的专长，开发出一系列优势产品。他们推出了原代和ipsC来源的神经细胞、干细胞和滋养层细胞，并开发出新型的转染试剂，能够以高效率将核酸导入干细胞和神经元。针对目前火热的CRISPR基因编辑，MTI-GlobalStem也推出了一系列导入试剂。
MTI-GlobalStem,isaleadingsupplierofcutting-edgetoolsandreagentsforthelifesciences.GlobalStemwasformedin2006andacquiredbyMolecularTransfer,Inc.(MTI)in2009(PressRelease).InNovember2016,MTI-GlobalStembecameapartofThermoFisherScientific(PressRelease).
In2002MolecularTransfer,Inc(MTI)wasestablishedbyasmallgroupofhighlyexperiencedbiotechnologyprofessionalsandscientistswiththevisionofprovidingsuperiorproductsintheareaoftransformationandtransfectionreagents.ThefoundingscientificmembersoftheMTIteamhaveahistoryofinnovationandsuccessinthedevelopmentofleading-edgetechnologiesintheareaoftransfection,transformation,nucleicacidchemistryandgeneexpressionarena.Theyareinventorsorco-inventorsonover50issuedpatentsandover70applications.Theyco-inventedandledthedevelopmentofLipofectamine®andLipofectAmine®2000duringtheirtenureatBRL/LifeTechnologies.TheyalsoledthedevelopmentandpioneeringcommercializationofvirtuallyalloftheofferingsinthefamousDH5α™andDH10B™linesincollaborationwithProfessorDougHanahanfromtheUniversityofCaliforniaSanFrancisco..TheformationofMTI-GlobalStemmergedMTI’sgroundbreakingtechnologiesintheareasoftransfection,transformationandgenedelivery,withGlobalStem’sexpertiseinstemcellandneurobiology.
MTIhascontinuedtodeveloppioneeringproductsintheareaoftransfectionthroughinventionandlicensingofenablingtechnologies.Theseinventionsarecombinedwithlicensedtechnologiesfromleadingacademiclaboratoriesthatfocusonnucleicaciddeliveryvectorsandnanoparticlestobedevelopedintonewcuttingedgetransfectionreagents.MTIhasbeenprovidinghighqualityandstateoftheartproductstotheresearchcommunitythroughseveralOEMmanufacturingrelationshipswithlarge,well-knownresearchproductcompanies.Intheareaoftransformation,MTIhasdevelopedandcommercializedchemicallycompetentcells(5alphaand10B)andelectrocompetentcells(electro10B).Aninnovative,ready-to-useandproprietaryElectro10Bincuvetteshasalsobeencommercialized(USPat#7,078,227,8,105,818).MTIexpandedintothestemcellandneuronalcellareasthroughitsacquisitionofGlobalStemin2009,toprovideneuronalcellsystemsandstem-cellproductstothelifesciencesresearchmarket.Productsincludeoptimizedandqualifiedneuralandstemcellgrowthmediaandsupplements,sera,feedercells,growthfactors,andassaykits,aswellastransfectionreagents.
MTI-GlobalStemhasanactiveresearchprogramthatutilizesexpertiseintransfection,neuroscienceandstemcellbiologytodevelopandsupplyscientistswiththenecessarytoolsandreagentstohelpadvancenewdiscoveriesanddevelopmentsinthelifesciences.Utilizingourintellectualpropertyandknow-how,andaspecializedteamofhighlyskilledandexperiencedscientists,wearefillingthegapwithprimaryandiPSC-derivedneuralcells,stemcellsandsupportingfeedercells,optimizedgrowthmediaandsupplements,andaninnovativeplatformofnoveltargetedreagentsusedtodelivernucleicacidsintostemcellsandneuronalcellswithmaximumefficiency.